Bronchiolitis Obliterans Syndrome: Alloimmune-Dependent and -Independent Injury with Aberrant Tissue Remodeling

Seminars in Thoracic and Cardiovascular Surgery

Volumn 20, Issue 2, 2008, Pages 173-182

  Sato, Masaaki ^a   Keshavjee, Shaf ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

chronic rejection; fibrosis; lung transplantation; regeneration; repair

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; AZITHROMYCIN; BASILIXIMAB; CD4 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; EVEROLIMUS; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MATRIX METALLOPROTEINASE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; PREDNISOLONE; RAPAMYCIN; STROMAL CELL DERIVED FACTOR 1; TACROLIMUS; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ALLOIMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTIREFLUX OPERATION; ARTICLE; AUTOIMMUNITY; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; DRUG MEGADOSE; GRAFT INFECTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; ISCHEMIA; LOW DRUG DOSE; LUNG ALVEOLUS EPITHELIUM; LUNG ASPIRATION; LUNG FIBROSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOID TISSUE; NONHUMAN; SURGEON; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

BRONCHIOLITIS OBLITERANS; GRAFT REJECTION; HUMANS; LUNG; LUNG TRANSPLANTATION;

EID: 49249092264     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2008.05.002     Document Type: Article

References (111)

1. Stewart S., Fishbein M.C., Snell G.I., et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 26 (2007) 1229-1242
2. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002) 297-310
3. Trulock E.P., Christie J.D., Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 26 (2007) 782-795
4. Heng D., Sharples L.D., McNeil K., et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 17 (1998) 1255-1263
5. Husain A.N., Siddiqui M.T., Holmes E.W., et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 159 (1999) 829-833
6. Chalermskulrat W., Neuringer I.P., Schmitz J.L., et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 123 (2003) 1825-1831
7. van den Berg J.W., Hepkema B.G., Geertsma A., et al. Long-term outcome of lung transplantation is predicted by the number of HLA-DR mismatches. Transplantation 71 (2001) 368-373
8. Lau C.L., Palmer S.M., Posther K.E., et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 69 (2000) 1520-1524
9. Girnita A.L., Duquesnoy R., Yousem S.A., et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 5 (2005) 131-138
10. SivaSai K.S., Smith M.A., Poindexter N.J., et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 67 (1999) 1094-1098
11. Lu K.C., Jaramillo A., Mendeloff E.N., et al. Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 22 (2003) 35-43
12. Reznik S.I., Jaramillo A., SivaSai K.S., et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 1 (2001) 228-235
13. Le Moine A., Goldman M., and Abramowicz D. Multiple pathways to allograft rejection. Transplantation 73 (2002) 1373-1381
14. Sundaresan S., Mohanakumar T., Smith M.A., et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 65 (1998) 648-653
15. Smith M.A., Sundaresan S., Mohanakumar T., et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 116 (1998) 812-820
16. Jaramillo A., Smith M.A., Phelan D., et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 67 (1999) 1155-1161
17. Palmer S.M., Davis R.D., Hadjiliadis D., et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 74 (2002) 799-804
18. Jaramillo A., Smith C.R., Maruyama T., et al. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 64 (2003) 521-529
19. Yasufuku K., Heidler K.M., Woods K.A., et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 73 (2002) 500-505
20. Bharat A., Fields R.C., Steward N., et al. CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant 6 (2006) 1799-1808
21. Burlingham W.J., Love R.B., Jankowska-Gan E., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 117 (2007) 3498-3506
22. Afzali B., Lombardi G., Lechler R.I., et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148 (2007) 32-46
23. Jaramillo A., Naziruddin B., Zhang L., et al. Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for bronchiolitis obliterans syndrome. Transplantation 71 (2001) 966-976
24. Goers T.A., Ramachandran S., Aloush A., et al. De novo production of K-{alpha}1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 180 (2008) 4487-4494
25. Kroshus T.J., Kshettry V.R., Savik K., et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 114 (1997) 195-202
26. Hadjiliadis D., Duane Davis R., Steele M.P., et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 17 (2003) 363-368
27. Daud S.A., Yusen R.D., Meyers B.F., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 175 (2007) 507-513
28. Andrade C.F., Waddell T.K., Keshavjee S., et al. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 5 (2005) 969-975
29. Palmer S.M., Burch L.H., Trindade A.J., et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 171 (2005) 780-785
30. DiGiovine B., Lynch 3rd J.P., Martinez F.J., et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol 157 (1996) 4194-4202
31. Zheng L., Whitford H.M., Orsida B., et al. The dynamics and associations of airway neutrophilia post lung transplantation. Am J Transplant 6 (2006) 599-608
32. Vos R., Vanaudenaerde B.M., Dupont L.J., et al. Transient airway colonization is associated with airway inflammation after lung transplantation. Am J Transplant 7 (2007) 1278-1287
33. D'Ovidio F., Mura M., Tsang M., et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 129 (2005) 1144-1152
34. Laan M., Cui Z.H., Hoshino H., et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 162 (1999) 2347-2352
35. Zheng L., Lam W.K., Tipoe G.L., et al. Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo. Eur Respir J 20 (2002) 170-176
36. Brocker V., Langer F., Fellous T.G., et al. Fibroblasts of recipient origin contribute to bronchiolitis obliterans in human lung transplants. Am J Respir Crit Care Med 173 (2006) 1276-1282
37. Tomasek J.J., Gabbiani G., Hinz B., et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3 (2002) 349-363
38. Hirabayashi T., Demertzis S., Schafers J., et al. Chronic rejection in lung allografts: immunohistological analysis of fibrogenesis. Transplant Int 1 suppl 9 (1996) S293-S295
39. El-Gamel A., Sim E., Hasleton P., et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 18 (1999) 828-837
40. Lama V.N., Harada H., Badri L.N., et al. Obligatory role for interleukin-13 in obstructive lesion development in airway allografts. Am J Pathol 169 (2006) 47-60
41. Keane M.P., Gomperts B.N., Weigt S., et al. IL-13 Is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol 178 (2007) 511-519
42. Wynn T.A. IL-13 effector functions. Annu Rev Immunol 21 (2003) 425-456
43. Kolodsick J.E., Peters-Golden M., Larios J., et al. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 29 (2003) 537-544
44. Adams B.F., Brazelton T., Berry G.J., et al. The role of respiratory epithelium in a rat model of obliterative airway disease. Transplantation 69 (2000) 661-664
45. Neuringer I.P., Sloan J., Budd S., et al. Calcineurin inhibitor effects on growth and phenotype of human airway epithelial cells in vitro. Am J Transplant 5 (2005) 2660-2670
46. Bellini A., and Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 87 (2007) 858-870
47. Phillips R.J., Burdick M.D., Hong K., et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114 (2004) 438-446
48. Neilson E.G. Setting a trap for tissue fibrosis. Nat Med 11 (2005) 373-374
49. Ward C., Forrest I.A., Murphy D.M., et al. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 60 (2005) 865-871
50. Keenan R.J., Konishi H., Kawai A., et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 60 (1995) 580-584 discussion 584-585
51. Sarahrudi K., Estenne M., Corris P., et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 127 (2004) 1126-1132
52. Snell G.I., and Westall G.P. Immunosuppression for lung transplantation: evidence to date. Drugs 67 (2007) 1531-1539
53. Ross D.J., Waters P.F., Levine M., et al. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 17 (1998) 768-774
54. McNeil K., Glanville A.R., Wahlers T., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 81 (2006) 998-1003
55. Azzola A., Havryk A., Chhajed P., et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 77 (2004) 275-280
56. Akselband Y., Harding M.W., and Nelson P.A. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 23 (1991) 2833-2836
57. Snell G.I., Valentine V.G., Vitulo P., et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 6 (2006) 169-177
58. Cahill B.C., Somerville K.T., Crompton J.A., et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 22 (2003) 169-176
59. Ussetti P., Laporta R., de Pablo A., et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 35 (2003) 1974-1977
60. Groetzner J., Wittwer T., Kaczmarek I., et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 81 (2006) 355-360
61. Iacono A.T., Keenan R.J., Duncan S.R., et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 153 (1996) 1451-1455
62. Iacono A.T., Johnson B.A., Grgurich W.F., et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 354 (2006) 141-150
63. Dusmet M., Maurer J., Winton T., et al. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 15 (1996) 948-954
64. Verleden G.M., Buyse B., Delcroix M., et al. Cyclophosphamide rescue therapy for chronic rejection after lung transplantation. J Heart Lung Transplant 18 (1999) 1139-1142
65. Villanueva J., Bhorade S.M., Robinson J.A., et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 5 (2000) 44-47
66. Fisher A.J., Rutherford R.M., Bozzino J., et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 5 (2005) 537-543
67. Gerhardt S.G., McDyer J.F., Girgis R.E., et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 168 (2003) 121-125
68. Khalid M., Al Saghir A., Saleemi S., et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 25 (2005) 490-493
69. Yates B., Murphy D.M., Forrest I.A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 172 (2005) 772-775
70. Verleden G.M., Vanaudenaerde B.M., Dupont L.J., et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 174 (2006) 566-570
71. Vanaudenaerde B.M., Wuyts W.A., Geudens N., et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 7 (2007) 76-82
72. Crowley S., and Egan J.J. Macrolide antibiotics and bronchiolitis obliterans following lung transplantation. Expert Rev Anti Infect Ther 3 (2005) 923-930
73. Cantu III E., Appel III J.Z., Hartwig M.G., et al. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 78 (2004) 1142-1151 discussion 1142-1151
74. Davis Jr. R.D., Lau C.L., Eubanks S., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 125 (2003) 533-542
75. D'Ovidio F., Singer L.G., Hadjiliadis D., et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 80 (2005) 1254-1260
76. Young L.R., Hadjiliadis D., Davis R.D., et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 124 (2003) 1689-1693
77. Johnson B.A., Iacono A.T., Zeevi A., et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 167 (2003) 1271-1278
78. Mach F. Statins as immunomodulatory agents. Circulation 109 (2004) II15-II17
79. Li Y., Koster T., Morike C., et al. Pravastatin prolongs graft survival in an allogeneic rat model of orthotopic single lung transplantation. Eur J Cardiothorac Surg 30 (2006) 515-524
80. Tan A., Levrey H., Dahm C., et al. Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 159 (1999) 220-227
81. Porter K.E., Turner N.A., O'Regan D.J., et al. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 64 (2004) 507-515
82. Boehler A., and Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 22 (2003) 1007-1018
83. Shirwan H. Chronic allograft rejection. Do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role?. Transplantation 68 (1999) 715-726
84. Bingaman A.W., and Farber D.L. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 4 (2004) 846-852
85. Sato M., Liu M., Anraku M., et al. Allograft airway fibrosis in the pulmonary milieu: a disorder of tissue remodeling. Am J Transplant 8 (2008) 517-528
86. Martinu T., Howell D.N., Davis R.D., et al. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest 129 (2006) 1016-1023
87. Motallebzadeh R., Bolton E.M., and Pettigrew G.J. Lymphoid tissue formation in allografts: innocent until proven guilty. Transplantation 85 (2008) 309-311
88. Puchelle E., Zahm J.M., Tournier J.M., et al. Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3 (2006) 726-733
89. Nord M., Schubert K., Cassel T.N., et al. Decreased serum and bronchoalveolar lavage levels of Clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients. Transplantation 73 (2002) 1264-1269
90. D'Ovidio F., Mura M., Ridsdale R., et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant 6 (2006) 1930-1938
91. Takeyama K., Tamaoki J., Chiyotani A., et al. Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in vitro. J Pharm Pharmacol 45 (1993) 756-758
92. Gomperts B.N., Belperio J.A., Rao P.N., et al. Circulating progenitor epithelial cells traffic via CXCR4/CXCL12 in response to airway injury. J Immunol 176 (2006) 1916-1927
93. Wong A.P., Dutly A.E., Sacher A., et al. Targeted cell replacement with bone marrow cells for airway epithelial regeneration. Am J Physiol Lung Cell Mol Physiol 293 (2007) L740-L752
94. Ramzy D., Rao V., Brahm J., et al. Cardiac allograft vasculopathy: a review. Can J Surg 48 (2005) 319-327
95. Luckraz H., Goddard M., McNeil K., et al. Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways?. Ann Thorac Surg 82 (2006) 1212-1218
96. Belperio J.A., Keane M.P., Burdick M.D., et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115 (2005) 1150-1162
97. Babu A.N., Murakawa T., Thurman J.M., et al. Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest 117 (2007) 3774-3785
98. Hu Y., Davison F., Zhang Z., et al. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation 108 (2003) 3122-3127
99. Parsonage G., Filer A.D., Haworth O., et al. A stromal address code defined by fibroblasts. Trends Immunol 26 (2005) 150-156
100. Kaufman J., Sime P.J., and Phipps R.P. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-gamma and IL-13, and implications for fibrosis. J Immunol 172 (2004) 1862-1871
101. Chesney J., Bacher M., Bender A., et al. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A 94 (1997) 6307-6312
102. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6 (2006) 205-217
103. Baddoura F.K., Nasr I.W., Wrobel B., et al. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 5 (2005) 510-516
104. Thaunat O., Field A.C., Dai J., et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci U S A 102 (2005) 14723-14728
105. Moyron-Quiroz J.E., Rangel-Moreno J., Hartson L., et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25 (2006) 643-654
106. Xu Q., Lee J., Jankowska-Gan E., et al. Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol 178 (2007) 3983-3995
107. Sattar H.A., Husain A.N., Kim A.Y., et al. The presence of a CD21+ follicular dendritic cell network distinguishes invasive Quilty lesions from cardiac acute cellular rejection. Am J Surg Pathol 30 (2006) 1008-1013
108. de Perrot M., Liu M., Waddell T.K., et al. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 167 (2003) 490-511
109. Fiser S.M., Tribble C.G., Long S.M., et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 73 (2002) 1041-1047 discussion 1047-1048
110. Martins S., de Perrot M., Imai Y., et al. Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant model. Gene Ther 11 (2004) 1786-1796
111. Cypel M., Rubacha M., Sato M., et al. Adenoviral mediated interleukin 10(AdhIL-10) gene therapy in normothermic ex vivo lung perfusion. J Heart Lung Transplant 26 (2007) S212